Iparomlimab/Tuvonralimab: all 97 studies that test it
Page 1 of 1. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.
- Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingNCT07876154Phase 2
- Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerRecruitingNCT07867392Phase 2
- HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICCRecruitingNCT07841574Phase 2
- A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingNCT07828873Phase 2
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingNCT07782840Phase 2
- Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingNCT07738159Phase 2
- QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract CancerRecruitingNCT07733115Phase 2
- FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingNCT07729605Phase 3
- SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular CarcinomaNot yet recruitingNCT07668570Phase 4
- QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory StudyNot yet recruitingNCT07649473Phase 2
- QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung CancerNot yet recruitingNCT07636226Phase 2/3
- Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair DeficiencyNot yet recruitingNCT07595523Phase 2
- Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07533305Phase 2
- A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant ChemoimmunotherapyNot yet recruitingNCT07530549Phase 2
- Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruitingNCT07530445Phase 2
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07502027Phase 4
- Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07454018Phase 2
- An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLCRecruitingNCT07452003Not applicable
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian CancerNot yet recruitingNCT07432594Phase 2
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCRecruitingNCT07416058Phase 2
- Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT07413601Phase 2
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingNCT07384416Phase 2
- Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial CancerNot yet recruitingNCT07369986Phase 2
- QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRecruitingNCT07327788Phase 2
- Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRecruitingNCT07315854Phase 2
- QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric CancerNot yet recruitingNCT07315035Phase 2
- PULSAR Combined With Immunotherapy and ChemotherapyRecruitingNCT07291947Phase 1/2
- Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)RecruitingNCT07289997Phase 2
- Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 TrialNot yet recruitingNCT07286942Phase 2
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II TrialRecruitingNCT07286253Phase 2
- SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerRecruitingNCT07256236Phase 2
- Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast CancerNot yet recruitingNCT07246317Phase 2
- Iparomlimab/Tuvonralimab Injection Plus CCRT in LACCRecruitingNCT07232654Phase 2
- A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingNCT07205185Phase 2
- A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Not yet recruitingNCT07200947Phase 2
- A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer PatientsNot yet recruitingNCT07197697Phase 2
- Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingNCT07180160Phase 2
- Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingNCT07179900Phase 2
- The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CCNot yet recruitingNCT07172217Phase 2
- QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon CancerNot yet recruitingNCT07156682Phase 2
- QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody TherapyNot yet recruitingNCT07141186Phase 2
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Phase 2
- A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular CarcinomaNot yet recruitingNCT07115550Not applicable
- QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)Not yet recruitingNCT07113964Phase 2
- A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After ChemoradiotherapyRecruitingNCT07091305Phase 2
- Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPCRecruitingNCT07085234Phase 2
- A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.Not yet recruitingNCT07083375Phase 2
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingNCT07070713Phase 2
- Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaRecruitingNCT07070700Phase 2
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07049185Phase 2
- QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal CancerNot yet recruitingNCT07025239Phase 3
- QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRCNot yet recruitingNCT07009145Phase 2
- Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingNCT07007728Phase 2
- Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
- INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell CarcinomaRecruitingNCT07002346Phase 3
- Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical CancerNot yet recruitingNCT06986057Phase 2
- QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast CancerRecruitingNCT06967103Phase 2
- Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of RecurrenceNot yet recruitingNCT06958484Phase 2
- Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of RecurrenceRecruitingNCT06954116Phase 2
- QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic CancerRecruitingNCT06951997Phase 2
- A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationNot yet recruitingNCT06949761Phase 1/2
- Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic TumorsRecruitingNCT06941766Phase 1/2
- QL1706 in the Treatment of Advanced Bone and Soft Tissue SarcomaRecruitingNCT06939855Phase 2
- Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ AdenocarcinomaRecruitingNCT06932068Phase 2
- Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCRecruitingNCT06897046Phase 2
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06893887Not applicable
- An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with LenvatinibNot yet recruitingNCT06884982Phase 2
- QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06852456Phase 2
- QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular CarcinomaNot yet recruitingNCT06822985Phase 1
- a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.Not yet recruitingNCT06789796Phase 3
- SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver MetastasesRecruitingNCT06787183Phase 2
- QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDACNot yet recruitingNCT06750861Phase 2
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Phase 3
- Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2
- A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon CancerRecruitingNCT06686576Phase 3
- Surgery for Relapsed Ovarian Cancer in PrecisionNot yet recruitingNCT06602063Phase 1/2
- A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian CancerNot yet recruitingNCT06509971Phase 2
- Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruitingNCT06446388Phase 2
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerNot yet recruitingNCT06404463Phase 2
- A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT05976568Phase 2/3
- A Phase II Study of CRT Combined With QL1706 in ESCC PatientsRecruitingNCT05490719Phase 2
- A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.RecruitingNCT05487391Phase 3
- QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerRecruitingNCT05446883Phase 3
- Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal JunctionActive, not recruitingNCT07776639Phase 2
- QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract TumorsActive, not recruitingNCT06892925Phase 2
- Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal MetastasisActive, not recruitingNCT06809530Phase 1/2
- A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung CancerActive, not recruitingNCT05690945Phase 3
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05603039Phase 1/2
- A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal CarcinomaActive, not recruitingNCT05576272Phase 2/3
- A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical CancerStatus unknownNCT05557565Phase 2
- A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerActive, not recruitingNCT05329025Phase 2
- Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05309629Phase 2
- A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2
- Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical CancerStatus unknownNCT05179317Phase 2
- A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid TumorsStatus unknownNCT05171790Phase 1
- A Study of QL1706 in Subjects With Advanced Malignant TumorStatus unknownNCT04296994Phase 1
- A Study of PSB205 in Subjects With Advanced Solid TumorsStatus unknownNCT03986606Phase 1